Progenics Pharma (PGNX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q1 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $3.27 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- NewLake Capital Partners, Inc. (NLCP) Misses Q2 EPS by 9c
- ArcelorMittal (MT) Tops Q3 EPS by 36c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
